Remove 2023 Remove Nuclear Medicine Remove Radiopharmaceuticals
article thumbnail

IMV: Nuclear medicine procedure volumes decrease

AuntMinnie

Total nuclear medicine patient study volumes decreased by 5.7% between 2021 and 2023, with a 10.7% Two-year compound annual growth rates (CAGR) between 2021 and 2023 show an overall average 2.9% Specifically considering cardiovascular nuclear medicine procedures, total procedures have decreased by 7.1%

article thumbnail

IMV: PET scan volumes continue to grow

AuntMinnie

In 2023 compared with 2022, the total volume of positron emission tomography (PET) scans increased 10.2% In 2023, the average number of PET scans per fixed PET site (versus mobile PET) increased 6.7% from 1,401 estimated PET scans per system in 2022 to 1,495 in 2023. Davin Korstjens. physicians reading PET scans per site.

PET Scan 290
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The rise of theranostics: Part 5 -- Advice from center administrators

AuntMinnie

As nuclear medicine therapies gain stature compared to nuclear medicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. A shortage of nuclear medicine technologists means a theranostics center may need to limit its patient volume.

article thumbnail

Meet the Minnies 2024 finalists

AuntMinnie

Elliot Fishman, MD, Johns Hopkins Medicine The second finalist is Elliot Fishman, MD, a category for which he took the trophy in 2001, 2007, 2014, and 2017. Louis, MO A first-time Minnies finalist, Dmitry Beyder exemplifies how the role of the nuclear medicine technologist can evolve. Elliot Fishman, MD. Dmitry Beyder.

article thumbnail

The rise of theranostics: Part 2 -- Moving into communities

AuntMinnie

A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. He also helped lead the theranostics conference at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 midwinter meeting. However, few freestanding theranostics centers exist today. Hope added.

article thumbnail

First Ever Investigational 18F-CD8 PET Radiopharmaceutical Aims to Predict and Monitor Early Response to Cancer Immunotherapies

Imaging Technology

The clinical trial will use this investigational radiopharmaceutical to help understand if patients have CD8+ T cells in their tumors and will, therefore, be more likely to respond to immune checkpoint inhibitors, the main class of immunotherapies currently approved for use. Lancet Oncology 2023; 24(3): e133-e143.

article thumbnail

Meet the Minnies 2024 semifinal candidates

AuntMinnie

Horowitz, et al, Medical Hypotheses , October 13, 2023. Plesner, et al, Radiology , September 26, 2023. Kochanova, et al, Scientific Reports , September 19, 2023. Huang, et al, JAMA Network Open , October 5, 2023. Luthria, et al, Journal of Nuclear Medicine , October 26, 2023.